Daunorubicin and cytarabine with gemtuzumab ozogamicin for acute myeloid leukaemia (AML)

Acute myeloid leukaemia (AML) is a fast-growing blood cancer that involves the white blood cells. Daunorubicin + cytarabine + gemtuzumab ozogamicin is a combination of medicines used to treat AML.

We cover what this treatment is, who might have it and how to have it. We also cover its main side effects and any special precautions you may need to take while you’re on it.

You can order printed copies of this leaflet free to UK addresses.

Visit our website to download this leaflet or any of our other resources.

All our information is available free of charge to people affected by leukaemia, myeloproliferative neoplasms or myelodysplastic syndromes in the UK. It costs us approximately £3 to provide one booklet. Please consider adding a donation to your order if you can.